Elicio Therapeutics (ELTX) to Release Earnings on Tuesday

Elicio Therapeutics (NASDAQ:ELTX) will likely be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Elicio Therapeutics to post earnings of ($0.49) per share for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:00 PM ET.

Elicio Therapeutics (NASDAQ:ELTX) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02).

Elicio Therapeutics Trading Down 1.1%

Shares of Elicio Therapeutics stock traded down $0.12 during midday trading on Tuesday, reaching $10.66. The company had a trading volume of 48,013 shares, compared to its average volume of 129,204. The stock has a fifty day moving average price of $11.28 and a 200 day moving average price of $9.51. The company has a debt-to-equity ratio of 5.75, a current ratio of 2.38 and a quick ratio of 2.38. The firm has a market cap of $199.25 million, a PE ratio of -4.07 and a beta of 1.12. Elicio Therapeutics has a fifty-two week low of $4.85 and a fifty-two week high of $14.93.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a research note on Wednesday, April 15th. They issued a “buy” rating and a $20.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a research note on Friday, April 24th. Rodman & Renshaw raised Elicio Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. HC Wainwright boosted their price target on Elicio Therapeutics from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Finally, Wall Street Zen raised Elicio Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Hedge Funds Weigh In On Elicio Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its stake in Elicio Therapeutics by 186.8% in the third quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock valued at $39,000 after buying an additional 2,335 shares during the period. Raymond James Financial Inc. acquired a new position in Elicio Therapeutics in the second quarter valued at approximately $46,000. Summit Financial LLC acquired a new position in Elicio Therapeutics in the fourth quarter valued at approximately $80,000. HighTower Advisors LLC bought a new stake in shares of Elicio Therapeutics during the fourth quarter valued at approximately $89,000. Finally, Jane Street Group LLC bought a new stake in shares of Elicio Therapeutics during the first quarter valued at approximately $92,000. 35.03% of the stock is owned by institutional investors and hedge funds.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.